Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension

BACKGROUND: Macitentan, a dual endothelin receptor antagonist (ERA), was approved in 2014 for the treatment of adults with idiopathic pulmonary arterial hypertension (PAH). Once-per-day dosing and low potential hepatic toxicity make macitentan an appealing therapeutic option for children with PAH, b...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cardiovasc Diagn Ther
Main Authors: Schweintzger, Sabrina, Koestenberger, Martin, Schlagenhauf, Axel, Grangl, Gernot, Burmas, Ante, Kurath-Koller, Stefan, Pocivalnik, Mirjam, Sallmon, Hannes, Baumgartner, Daniela, Hansmann, Georg, Gamillscheg, Andreas
Formato: Artigo
Idioma:Inglês
Publicado: AME Publishing Company 2020
Assuntos:
Original Article on Right Ventricular Dysfunction
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7666951/
https://ncbi.nlm.nih.gov/pubmed/33224780
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/cdt.2020.04.01
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares